44 related articles for article (PubMed ID: 10190008)
1. [Production of mediators enhancing antineoplastic cytostatic activity of bone marrow cells by activated lymphocytes].
Seledtsov VI; Taraban VIa; Seledtsova GV; Seniukov VV; Samarin DM; Kashchenko EA
Biull Eksp Biol Med; 1999 Jan; 127(1):63-5. PubMed ID: 10190008
[No Abstract] [Full Text] [Related]
2. [Production by activated lymphocytes of mediators increasing the antitumor cytostatic activity of bone marrow cells].
Seledtsov VI; Taraban VIa; Seledtsova GV; Seniukov VV; Samarin DM; Kashchenko EA; Kozlov VA
Biull Eksp Biol Med; 1998 Jun; 125(6):660-2. PubMed ID: 9693761
[No Abstract] [Full Text] [Related]
3. [Comparative study of the antineoplastic cytostatic and natural suppressive activity of bone marrow cells].
Seledtsov VI; Seledtsova GV; Taraban VIa; Seniukov VV; Samarin DM; Poveshchenko OV; Kashchenko EA; Kozlov VA
Biull Eksp Biol Med; 1998 Apr; 125(4):437-9. PubMed ID: 9631731
[No Abstract] [Full Text] [Related]
4. [Suppressor and antineoplastic activity of the bone marrow and spleen cells in aging AKR mice].
Bel'skiĭ IuP; Bel'skaia NV; Danilets MG; Stal'bovskaia ES; Kusmartsev SA
Biull Eksp Biol Med; 1999 Apr; 127(4):452-4. PubMed ID: 10367135
[No Abstract] [Full Text] [Related]
5. Induction of cytotoxic T lymphocytes by dendritic cells pulsed with murine leukemic cell RNA.
Jung CW; Kwon JH; Seol JG; Park WH; Hyun JM; Kim ES; Kim ST; Lee SJ; Kim BK; Lee YY
Am J Hematol; 2004 Mar; 75(3):121-7. PubMed ID: 14978690
[TBL] [Abstract][Full Text] [Related]
6. Critical impact of the kinetics of dendritic cells activation on the in vivo induction of tumor-specific T lymphocytes.
Camporeale A; Boni A; Iezzi G; Degl'Innocenti E; Grioni M; Mondino A; Bellone M
Cancer Res; 2003 Jul; 63(13):3688-94. PubMed ID: 12839960
[TBL] [Abstract][Full Text] [Related]
7. Induction of soluble antitumoral mediators by synthetic analogues of bacterial lipoprotein in bone marrow-derived macrophages from LPS-responder and -nonresponder mice.
Pfannes SD; Müller B; Körner S; Bessler WG; Hoffmann P
J Leukoc Biol; 2001 Apr; 69(4):590-7. PubMed ID: 11310845
[TBL] [Abstract][Full Text] [Related]
8. Mice with a targeted mutation in lymphotoxin-alpha exhibit enhanced tumor growth and metastasis: impaired NK cell development and recruitment.
Ito D; Back TC; Shakhov AN; Wiltrout RH; Nedospasov SA
J Immunol; 1999 Sep; 163(5):2809-15. PubMed ID: 10453025
[TBL] [Abstract][Full Text] [Related]
9. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.
Asavaroengchai W; Kotera Y; Koike N; Pilon-Thomas S; Mulé JJ
Biol Blood Marrow Transplant; 2004 Aug; 10(8):524-33. PubMed ID: 15282530
[TBL] [Abstract][Full Text] [Related]
10. [Study of anti-myeloma activity of interleukin-2 activated bone marrow in vitro].
Liu W; Chen SL; Liu JW; Li X; Xia CQ; Qi M
Zhonghua Xue Ye Xue Za Zhi; 2005 Apr; 26(4):205-8. PubMed ID: 15949260
[TBL] [Abstract][Full Text] [Related]
11. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses.
Yang AS; Lattime EC
Cancer Res; 2003 May; 63(9):2150-7. PubMed ID: 12727833
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory activity of curcumin: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production in vitro.
Gao X; Kuo J; Jiang H; Deeb D; Liu Y; Divine G; Chapman RA; Dulchavsky SA; Gautam SC
Biochem Pharmacol; 2004 Jul; 68(1):51-61. PubMed ID: 15183117
[TBL] [Abstract][Full Text] [Related]
13. Enhanced antitumor immunity by murine cytokine activated T lymphocytes after cocultured with bone marrow derived dendritic cells pulsed with whole tumor lysates.
Zhang S; Wang Q; Li WF; Wang HY; Zhang HJ
Leuk Res; 2004 Oct; 28(10):1085-8. PubMed ID: 15289022
[TBL] [Abstract][Full Text] [Related]
14. Augmented Induction of CD4+CD25+ Treg using monoclonal antibodies to CD200R.
Gorczynski RM; Lee L; Boudakov I
Transplantation; 2005 May; 79(9):1180-3. PubMed ID: 15880066
[TBL] [Abstract][Full Text] [Related]
15. [TNF-alpha production and antitumor effect of rhIL-2-activated bone marrow cells].
Zhu B; Yang P; Sun B
Zhonghua Xue Ye Xue Za Zhi; 1998 Nov; 19(11):581-2. PubMed ID: 11263342
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow CD8 T cells are in a different activation state than those in lymphoid periphery.
Di Rosa F; Santoni A
Eur J Immunol; 2002 Jul; 32(7):1873-80. PubMed ID: 12115606
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic bone marrow inhibits T-cell activation and clonal expansion in vitro.
George JF; Lu A; Thomas JM; Kirklin JK; Pinderski LJ
Transplantation; 2003 Jul; 76(1):237-43. PubMed ID: 12865816
[TBL] [Abstract][Full Text] [Related]
18. Bone marrow as a priming site for T-cell responses to blood-borne antigen.
Feuerer M; Beckhove P; Garbi N; Mahnke Y; Limmer A; Hommel M; Hämmerling GJ; Kyewski B; Hamann A; Umansky V; Schirrmacher V
Nat Med; 2003 Sep; 9(9):1151-7. PubMed ID: 12910264
[TBL] [Abstract][Full Text] [Related]
19. Perisinusoidal B cells in the bone marrow participate in T-independent responses to blood-borne microbes.
Cariappa A; Mazo IB; Chase C; Shi HN; Liu H; Li Q; Rose H; Leung H; Cherayil BJ; Russell P; von Andrian U; Pillai S
Immunity; 2005 Oct; 23(4):397-407. PubMed ID: 16226505
[TBL] [Abstract][Full Text] [Related]
20. Veto activity of activated bone marrow does not require perforin and Fas ligand.
Chrobak P; Gress RE
Cell Immunol; 2001 Mar; 208(2):80-7. PubMed ID: 11333140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
